1 / 9

‘White Rose’ Teenage and Young Adult Cancer Research Group

‘White Rose’ Teenage and Young Adult Cancer Research Group. Supported by the Laura Crane Trust Dr Bob Phillips Dr Alison Eastwood Prof Lesley Stewart. What is a systematic review?. “Systematic reviews identify, describe, appraise and synthesise research evidence from individual studies” …

yeriel
Download Presentation

‘White Rose’ Teenage and Young Adult Cancer Research Group

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ‘White Rose’ Teenage and Young Adult Cancer Research Group Supported by the Laura Crane Trust Dr Bob Phillips Dr Alison Eastwood Prof Lesley Stewart

  2. What is a systematic review? • “Systematic reviews identify, describe, appraise and synthesise research evidence from individual studies” … • “they follow a strict protocol to ensure that … the original studies are appraised and synthesised in a valid way.” • “These methods minimise the risk of bias and are transparent, enabling replication.”

  3. What are systematic reviews good for? • Systematic reviews: • avoid duplication of research • identify gaps in current knowledge • learn from the practical problems in previous research • learn from the methodological shortcomings in previous research • identify the best objectives for the new research

  4. Antiemetics for nausea and vomiting Ongoing Bone marrow for malignancy1998 Breast: cancer guidance2002 Breast cancer: management1996 Cancer waiting times2005 Capecitabine for breast cancer2003 Colorectal: cancer guidance update2004 Colorectal: cancer guidance1997 Communicating with people who have cancer2000 COX-2 inhibitors in bladder cancer2004 Docetaxel for prostate cancer2007 Double reading mammograms2001 The evidence behind the Cancer Plan2007 Faecal occult blood tests2007 Gynaecological: cancer guidance1999 Haematological: cancer guidance2003 Head and neck: cancer guidance2004 Home parenteral nutrition 1997 Lung: cancer guidance1998 Ovarian cancer screening1998 Parenteral oestrogen for prostate cancer2006 Photodynamic therapy2003 Prostate biopsy methods2005 Psychosocial interventions in cancer and heart disease2005 Retinoblastoma2005 Risk stratification of febrile neutropenia in childhood Ongoing Screening for prostate cancer1997 Second-line treatments for advanced ovarian cancer2006 Taxanes for breast cancer: update2001 Taxanes for ovarian and breast cancer2000 Taxanes for ovarian cancer: update2003 Topotecan for ovarian cancer2001 Topotecan and PLDH for ovarian cancer2002 Trastuzumab for breast cancer2002 Trastuzumab (Herceptin) in the media 2008 Upper gastro-intestinal: cancer guidance2000 Urological: cancer guidance2002 Vinorelbine for breast cancer2002 CRD and Cancer

  5. CRD and Cancer • Scoping • Specific health interventions • Diagnostics and screening • Service delivery and organisation • Risk stratification and prognostics

  6. What can CRD offer the Laura Crane TYAC Research Group? • Develop protocols & undertake systematic reviews to: • avoid duplication of research • identify gaps in current knowledge • learn from the practical problems in previous research • learn from the methodological shortcomings in previous research • identify the best objectives for the new research

  7. Thank you Dr Bob Phillips Dr Alison Eastwood Prof Lesley Stewart rp532@york.ac.uk

More Related